Evaluate the expected performance of Amgen (AMGN) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for ...

Amgen Inc. (NASDAQ:AMGN) is one of the best stem cell therapy stocks to buy. Canaccord initiated coverage of Amgen Inc.

In this article, we will list the 5 Best Stem Cell Therapy Stocks to Buy. If you wish to see the methodology behind the ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Amgen’s AMGN stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

This morning a "Potential Dividend Run Alert" went out for Amgen Inc (NASD: AMGN), at our DividendChannel.com Dividend Alerts service (a free email alerts feature). Let's look at the situation in ...

Looking ahead to 2030, our model projects AMGN could trade at an average price of $537.89, with a potential range between $403.41 and $672.36. This represents a potential 57.0% return from today's ...

Amgen Inc. AMGN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and has recommended conditional marketing ...

Amgen’s (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in ...